Search Result

Results for "

MCF-7 and MDA-MB-231

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (25) Aurora Kinase (1) Bacterial (1) Bcl-2 Family (5) Carbonic Anhydrase (1) Caspase (1) CDK (2) Cytochrome P450 (2) E3 Ligase Ligand-Linker Conjugates (1) EGFR (4) Endogenous Metabolite (1) Epigenetic Reader Domain (1) Estrogen Receptor/ERR (2) FGFR (1) Fungal (1) Galectin (1) HDAC (2) Histone Methyltransferase (2) HSP (2) Ligands for E3 Ligase (1) MDM-2/p53 (1) Melatonin Receptor (1) Mitochondrial Metabolism (1) Mixed Lineage Kinase (1) Necroptosis (2) NF-κB (2) NO Synthase (1) Nuclear Hormone Receptor 4A/NR4A (1) PARP (2) PDGFR (1) Photosensitizer (1) PI3K (2) PKC (2) PPAR (1) PROTACs (2) Reactive Oxygen Species (2) RIP kinase (1) Src (2) Topoisomerase (5) Transmembrane Glycoprotein (1) Tyrosinase (2) VEGFR (5)
By Research Areas:	Cancer (52) Cardiovascular Disease (1) Endocrinology (3) Infection (2) Inflammation/Immunology (1)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Polymers (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Click Chemistry

Oligonucleotides

Targets Recommended: SDCBP Fat Mass and Obesity-associated Protein (FTO)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1029

Danazol 4 Publications Verification	PKC Apoptosis Tyrosinase	Endocrinology Cancer
Danazol inhibits the proliferation of cancer cell MDA-MB-231 and MCF-7 with IC₅₀ of 65 µg/mL and 31 µg/mL. Danazol arrests the cell cycle at G1 phase, induces apoptosis in MDA-MB-231 through PKCα signaling pathway .

HY-N6990

Anhydrosecoisolariciresinol	Others	Cancer
Anhydrosecoisolariciresinol is from the flower of Wedelia biflora, has anti-tumor activities . Anhydrosecoisolariciresinol decreases the growth of human breast cancer MCF-7 and MDA-MB-231 cell lines .

HY-B1029R

Danazol (Standard)	Tyrosinase PKC Apoptosis	Endocrinology Cancer
Danazol standard inhibits the proliferation of cancer cell MDA-MB-231 and MCF-7 with IC₅₀ of 65 µg/mL and 31 µg/mL. Danazol arrests the cell cycle at G1 phase, induces apoptosis in MDA-MB-231 through PKCα signaling pathway .

HY-158387

Anticancer agent 214	Topoisomerase	Cancer
Anticancer agent 214 (2) is a Camptothecin compound, with IC₅₀ values of 2.6 nM and 15.7 nM in MCF-7 cells and MDA-MB-231 cells, respectively .

HY-158388

Anticancer agent 215	Topoisomerase	Cancer
Anticancer agent 215 (1) is a Camptothecin compound, with IC₅₀ values of 5.2 nM and 8.2 nM in MCF-7 cells and MDA-MB-231 cells, respectively .

HY-158389

Anticancer agent 216	Topoisomerase	Cancer
Anticancer agent 216 (34A) is a Camptothecin compound, with IC₅₀ values of 9.6 nM and 11.6 nM in MCF-7 cells and MDA-MB-231 cells, respectively .

HY-158390

Anticancer agent 217	Topoisomerase	Cancer
Anticancer agent 217 (35B) is a Camptothecin compound, with IC₅₀ values of 6.2 nM and 7.1 nM in MCF-7 cells and MDA-MB-231 cells, respectively .

HY-123081

Eburicol	Bacterial	Infection Cancer
Eburicol is a natural sterol with antiproliferative and antimicrobial activities. Eburicol has a weak antimicrobial activity against S. aureus. Eburicol shows cytotoxic effect against MCF-7 and MDA-MB-231 cell lines .

HY-168720

Apoptosis inducer 32	Apoptosis	Cancer
Apoptosis inducer 32 (Compound 7g) is an apoptosis inducer with a K_D of 42 μM, showing anti-tumor activity. Apoptosis inducer 32 caused significant cellular morphological changes in MDA-MB-231 cells, including membrane bubbling, nuclear fragmentation, and apoptotic body formation. The IC₅₀ of Apoptosis inducer 32 in MCF-7, MDA-MB-231, and HEK cells is 4.77, 6.56 and 337.8 μM respectively .

HY-161868

DLC-50	PARP HDAC Apoptosis	Cancer
DLC-50 is a dual inhibitor for PARP-1 and HDAC-1 with IC₅₀ of 1.2 nM and 31 nM. DLC-50 inhibits the proliferation of cancer cells MDA-MB-436, MDA-MB-231, and MCF-7 with IC₅₀ of 0.3, 2.7 and 2.41 μM. DLC-50 induces apoptosis in MDA-MB-231, arrests the cell cycle at G2 phase .

HY-161769

HL435	PROTACs Epigenetic Reader Domain Apoptosis	Cancer
HL435 is a heterobifunctional molecule that degrades BRD4 by linking to JQ1, with DC₅₀ of 11.9 nM and 21.9 nM, in MDA-MB-231 and MCF-7 cells, respectively. HL435 inhibits the proliferation of MDA-MB-231, MCF-7, 22Rv1 and A549, arrests the cell cycle and induces apoptosis. HL435 exhibits antitumor activity in mouse model. (Pink: ligand for target protein JQ-1 (HY-78695); Black: linker (HY-W004640); blue: ligand for E3 ligase HL389 (HY-161770))

HY-162751

Anticancer agent 249	HSP Apoptosis	Cancer
Anticancer agent 249 (Compound 89) is an inhibitor for Hsp90β with IC₅₀ of 16.5 μM in PC3MM2 cell. Anticancer agent 249 inhibits proliferation of cancer cells MCF-7, T47D, MDA-MB-231, MDA-MB-468 and SKBr3 with IC₅₀ of 1.8-5.3 μM. Anticancer agent 249 induces apoptosis in MDA-MB-231. Anticancer agent 249 exhibits antitumor efficacy in mice .

HY-173075

Anticancer agent 267	RIP kinase Mixed Lineage Kinase Necroptosis	Cancer
Anticancer agent 267 (Compound 5q) is the activator for RIPK3 and MLKL. Anticancer agent 267 inhibits the proliferation in a variety of cancer cell lines (IC₅₀ for MDA-MB-231, MDA-MB-486 and MCF-7 is 9.79, 10.77 and 5.94 μM, respectively), arrests cell cycle at subG1 phase, and induces necroptosis in cell MDA-MB-231. Anticancer agent 267 exhibits antitumor activity in mouse xenograft models .

HY-120275

CYD-2-11	Bcl-2 Family Apoptosis	Cancer
CYD-2-11 is a selective Bax agonist with a K_i value of 34.1 nM. CYD-2-11 induces cell apoptosis and shows antiproliferative activity to breast cancer MDA-MB-231 and MCF-7 cell lines with IC₅₀ values of 3.22 and 3.81 μM, respectively. CYD-2-11 suppresses tumor growth in MDA-MB-231 tumor models. CYD-2-11 can be used for the research of breast and lung cancer .

HY-169408

EGFR-IN-137	Cytochrome P450 EGFR Apoptosis	Cancer
EGFR-IN-137 (Compound 4c) is an inhibitor for aromatase and EGFR with IC₅₀s of 1.67 μg/mL and 0.08 μg/mL. EGFR-IN-137 inhibits the proliferation of cancer cell MCF-7 and MDA-MB-231 with IC₅₀s of 1.62 µM and 4.14 µM. EGFR-IN-137 arrests the cell cycle at G0/G1 phase in MDA-MB-231, and induces apoptosis through caspase-dependent pathway .

HY-156378

Aurora A inhibitor 3	Aurora Kinase	Cancer
Aurora A inhibitor 3 (Compound 5h) inhibits Aurora-A kinase with an IC₅₀ value of 0.78 μM. Aurora A inhibitor 3 is cytotoxic, with GI₅₀ values of 0.12 μM and 0.63 μM for MCF-7 and MDA-MB-231 cells, respectively .

HY-161770

HL389	Ligands for E3 Ligase	Cancer
HL389 inhibits proliferation of cancer cells MDA-MB-231 and MCF-7, with IC₅₀ of 11.39 μM and 9.66 μM. HL389 can be utilized as the ligand for E3 ligase for the synthesis of PROTAC degrader HL435 (HY-161769) .

HY-144306

ERα degrader 4	Estrogen Receptor/ERR Apoptosis	Cancer
ERα degrader 4 is an excellent and selective estrogen receptor α (ERα) degrader (IC₅₀ of 0.31, 0.41 and 0.48 μM in MDA-MB-231, MCF-7 and MCF-7/ADR cells, respectively). ERα degrader 4 has potent inhibitory activity against MCF-7 cell lines. ERα degrader 4 is a potential SERDs candidate for the research of breast cancer .

HY-168901

Hck-IN-2	Src	Cancer
Hck-IN-2 (Compound 8e) is an HCK inhibitor. Hck-IN-2 is cytotoxic to tumor cells, with IC₅₀ values of 19.58 μM and 1.42 μM against MDA-MB231 and MCF-7, respectively. Hck-IN-2 has anti-tumor activity .

HY-155969

EGFR-IN-83	EGFR Apoptosis	Cancer
EGFR-IN-83 (Compound 9) is an EGFR inhibitor (IC₅₀: 2.53 nM). EGFR-IN-83 has antiproliferative activity against MCF-7 and MDA-MB-231 cells, with IC₅₀ of 2.50 μM and 1.96 μM. EGFR-IN-83 can induce cell apoptosis .

HY-161755

Anticancer agent 232	Endogenous Metabolite	Cancer
Anticancer agent 232 (compound 12f) is a glycohybrid designed using 1-azidoglycosides derived from d-glucose, d-galactose, and d-mannose. The IC₅₀ values of anticancer agent 232 against MCF-7 and MDA-MB231 cells are 1.05 μM and 18.03 μM, respectively .

HY-152945

Antiproliferative agent-22	NF-κB	Cancer
Antiproliferative agent-22 (compound 2) is an anticancer agent. Antiproliferative agent-22 shoes anti-proliferative activities against MCF-7, MDA-MB-231 and MDA-MB-468 cells with IC₅₀ values of 6.2 μM, 3.3 μM and 3.3 μM, respectively .

HY-157151

iPRMT1	Histone Methyltransferase	Cancer
iPRMT1 is a potent and selective PRMT1 inhibitor for breast cancer research. iPRMT1 inhibits breast cancer cell growth in vitro and in vivo with EC₅₀ values of 90, 70, and 9 nM in MCF7, T47D, and MDA-MB-231 cells, respectively .

HY-N2741

Vitexin B-1	Bcl-2 Family	Cancer
Vitexin B-1 is an inhibitor of Bcl-2 and the agonist of Caspase. Vitexin B-1 has cytotoxic effect and induces apoptosis in MCF-7, ZR-75-1, MDA-MB-231, and COC1 cells with IC₅₀s of 3.2, 2.1, 1.8 and 0.39 μM, respectively .

HY-138210

N,O-Diacetyltyramine	Fungal	Infection
N,O-Diacetyltyramine is a compound with antibacterial activity and cytotoxicity that can be isolated from the actinomycete Pseudonocardia endophytica VUK-10. N,O-Diacetyltyramine has antibacterial activity against Gram-positive and Gram-negative bacteria and fungi. N,O-Diacetyltyramine is cytotoxic to MDA-MB-231, HeLa, MCF-7 and OAW-42 cells .

HY-159122

CA IX-IN-2	Carbonic Anhydrase Reactive Oxygen Species Apoptosis	Cancer
CA IX-IN-2 (Compound 9o) is an inhibitor for carbonic anhydrase (CA), that inhibits CA IX, CA XII and CA II with an IC₅₀ of 5.6, 7.4 and 430 nM, respectively. CA IX-IN-2 inhibits the proliferation of cancer cell HCT-116, SW480, MDA-MB 231 and MCF-7, with IC₅₀s of 14.63-29.33 μM. CA IX-IN-2 intercalates DNA, arrests cell cycle at G1/S phase, and induces apoptosis in MDA-MB-231. CA IX-IN-2 affects the mitochondrial membrane potential (MMP), increases the intracellular ROS levels, causes mitochondrial damage, and inhibits the cell migration of MDA-MB-231. CA IX-IN-2 exhibits antitumor efficacy in mouse models .

HY-148368

CYD-4-61	Bcl-2 Family Apoptosis	Cancer
CYD-4-61 is a novel Bax activator used for breast cancer research. CYD-4-61 inhibits triple-negative breast cancer MDA-MB-231 and ER-positive breast cancer MCF-7 cell lines proliferation. CYD-4-61 activates Bax protein to induce cytochrome c release and regulate apoptotic biomarkers, leading to cancer cell apoptosis .

HY-116904

Anticancer agent 253	Apoptosis Akt	Cancer
Anticancer agent 253 (Compound 26) has anti-cancer activity against breast cancer cells, with IC₅₀s of 6 μM (MCF-7), 10 μM (MDA-MB-231) and 6.4 μM (4T1 cells). Anticancer agent 253 arrests cell cycle and induces mitochondria-mediated apoptosis in cancer cells. Anticancer agent 253 inhibits Akt phosphorylation in human breast and prostate cancer .

HY-161855

VEGFR-2-IN-50	VEGFR Apoptosis	Cancer
VEGFR-2-IN-50 (Compound 10f) is a VEGFR-2 inhibitor and apoptosis inducer, with an IC₅₀ value of 0.33 μM. VEGFR-2-IN-50 (Compound 10f) has growth inhibitory activity on MCF-7 and MDA-MB-231 breast cancer cell lines, with IC₅₀ values of 19.86 μM and 10.88 μM, respectively, which is expected to be used in the study of breast cancer diseases .

HY-146103

Antiproliferative agent-7	Apoptosis Reactive Oxygen Species	Cancer
Antiproliferative agent-7 (compound 8f) is a potent anti-proliferative agent. Antiproliferative agent-7 has antiproliferative activity against cancer cell lines MCF-7, MDA-MB-231, HCT-116 and FR-2 with IC₅₀s of 3.5 μM, 15.54 μM, 30.43 μM and 34.8 μM, respectively. Antiproliferative agent-7 can increase ROS production and induce apoptosis .

HY-146452

Anticancer agent 57	Apoptosis	Cancer
Anticancer agent 57 (compound 14) potently inhibits MDA-MB-231, MDA-MB-468, and MCF-7 cell lines, with IC₅₀s of 6.43 ~ 8.00 μM. Anticancer agent 57 induces cell cycle arrest and significantly promotes apoptosis. Anticancer agent 57 inhibits tumor growth in nude mice xenografted with MADMB-231 cells. Anticancer agent 57 can be used for researching triple negative breast cancer (TNBC) .

HY-155113

PROTAC Hsp90α degrader 1	PROTACs HSP	Cancer
PROTAC Hsp90α degrader 1 (Compound X10g) is a selective PROTAC Hsp90α degrader. PROTAC Hsp90α degrader 1 can be used for breast cancer research. PROTAC Hsp90α degrader 1 inhibits the proliferation of MDA-MB-231, MDA-MB-468, MCF-7, MX-1 cells with IC₅₀s of 51.48 μM, 16.46 μM, 8.93 μM, 11.95 μM respectively .

HY-171477

Metahexestrol	Estrogen Receptor/ERR	Cancer
Metahexestrol is an estrogen receptor (E2R) inhibitor with antitumor activity. It significantly inhibits the proliferation of estrogen receptor-positive MCF-7 human breast cancer cells (ED₅₀ = 1.0 μM). Additionally, Metahexestrol also exhibits inhibitory effects in estrogen receptor-negative MDA-MB-231 cells, and its antiproliferative activity cannot be reversed by estrogen, suggesting that its mechanism of action may be partially independent of the E2R pathway. Metahexestrol can be used in research on estrogen-dependent breast cancer .

HY-170955

HA-CD44 interaction inhibitor 3	Transmembrane Glycoprotein	Cancer
HA-CD44 interaction inhibitor 3 (compound 5d) is a Hyaluronic acid (HY-B0633A) (HA)-CD44 interaction inhibitor with antiproliferative activities. HA-CD44 interaction inhibitor 3 inhibits MDA-MB-231 (CD44++) cells and MCF-7 cells (CD44--) with EC₅₀s of 4.24 μM and 14.74 μM, respectively. HA-CD44 interaction inhibitor 3 shows the potential for cancer research .

HY-149636

Multi-target kinase inhibitor 2	EGFR CDK VEGFR	Cancer
Multi-target kinase inhibitor 2 (compound 5K) is a multi-targeted kinase inhibitor, and exhibits activity against EGFR, Her2, VEGFR2, and CDK2 enzymes, with IC₅₀ values ranging from 40 to 204 nM. Multi-target kinase inhibitor 2 shows cytotoxic effects were observed against HepG2, HeLa , MDA-MB-231 and MCF-7, with IC₅₀ of 41, 57, 51 and 59 μM. Multi-target kinase inhibitor 2 induces cell cycle arrest and apoptosis in HepG2 cells.

HY-161773

HL389-NHC2-PEG3-C2NH	E3 Ligase Ligand-Linker Conjugates	Cancer
HL389-NHC2-PEG3-C2NH inhibits proliferation of cancer cells MDA-MB-231 and MCF-7, with IC₅₀ of 11.39 μM and 9.66 μM. HL389-NHC2-PEG3-C2NH can be utilized as a conjugate of an E3 ligase ligand and a linker, for the synthesis of PROTAC degrader HL435 (HY-161769) .

HY-163434

PRMT5/EGFR-IN-1	EGFR Histone Methyltransferase	Cancer
PRMT5/EGFR-IN-1 (Compound 10p) is an orally active dual PRMT5/EGFR inhibitor, with IC₅₀s of 15.47 and 19.31 μM, respectively. PRMT5/EGFR-IN-1 exhibits antiproliferative activity against A549, MCF7, HeLa, and MDA-MB-231 cell lines. PRMT5/EGFR-IN-1 has favorable in vivo PK and PD properties. PRMT5/EGFR-IN-1 can significantly inhibit the growth of MCF7 orthotopic xenograft tumors .

HY-134997

4-Oxo Docosahexaenoic Acid 4-oxo DHA	PPAR	Cancer
4-oxo Docosahexaenoic acid (4-oxo DHA) is a putative metabolite of Docosahexaenoic acid (HY-B2167) with antiproliferative and PPARγ agonist activity. It inhibits the growth of several triple negative breast cancer cell lines (MCF-10F, trMCF, bsMCF, MDA-MB-231, and BT549) at 50-100 μM, however it increased proliferation of MCF-7 cells. 4-oxo DHA binds covalently to PPARγ and activates gene transcription in luciferase reporter assays and in dendritic cells with EC₅₀ values of approximately 8-16 μM.

HY-155965

VEGFR/PARP-IN-1	VEGFR PARP Apoptosis	Cancer
VEGFR/PARP-IN-1 (Compound 14b) is a VEGFR/PARP dual inhibitor (IC₅₀s: 191 nM and 60.9 nM respectively). VEGFR/PARP-IN-1 inhibits DNA damage repair, induces cell apoptosis, and arrests cell in the G2/M phase. VEGFR/PARP-IN-1 has good antiproliferative efficacy against BRCA wild-type breast cancer cells (IC₅₀: 4.1 and 3.5 μM for MDA-MB-231 and MCF-7 cells). VEGFR/PARP-IN-1 is an antitumor and anti-metastasis agent .

HY-161687

Cisplatin/Dasatinib prodrug-1	Src	Cancer
Cisplatin/Dasatinib prodrug-1 (Compound 3) is a prodrug of Cisplatin (HY-17394) and Dasatinib (HY-10181). Cisplatin/Dasatinib prodrug-1 exhibits antiproliferative activity against A2780, MDA-MB-231, MCF7, HCT116, RD, Thp1 and HL60 cancer cells with IC₅₀s of 0.1, 0.1, 0.36, 2.0, 0.4, 0.3 and 0.25 μM, respectively .

HY-156444

HDAC1/CDK7-IN-1	HDAC CDK Apoptosis	Cancer
HDAC1/CDK7-IN-1 (compound 8e) is a dual CDK7 and HDAC1 inhibitor with IC₅₀s of 893 nM and 248 nM, respectively. HDAC1/CDK7-IN-1 inhibits the growth cells of MDA-MB-231, MCF-7, A549, and HCT-116 cancer cells. HDAC1/CDK7-IN-1 induces cell cycle arrest and apoptosis in HCT-116 cells, as well as hindered the migration of HCT-116 cells .

HY-P10393

ERα17p ERα (295-311)	Apoptosis	Cancer
ERα17p (ERα 295-311) is the epitope of the CaM binding site on the estrogen receptor α (ER), which interacts with calmodulin (CaM) in a calcium-dependent manner. ERα17p regulates the migration of cancer cells MCF-7, SK-BR-3, T47D, and MDA-MB-231 through Rho/ROCK and PI3K/Akt signaling pathways. ERα17p inhibits proliferations of breast cancer cells, induces apoptosis, and inhibits tumor growth in mouse models .

HY-P10873

ST-CY14	Nuclear Hormone Receptor 4A/NR4A Mitochondrial Metabolism	Cancer
ST-CY14 is an inhibitor for Nur77-PPARγ interaction with an EC₅₀ of 3.15 μM, that binds to Nur77 (K_d=32 nM), blocks Nur77 from being ubiquitinated and degraded by PPARγ, reduces fatty acid uptake and mitochondrial respiration, and inhibits the transcription of CD36 and FABP4. ST-CY14 inhibits the proliferation and migration of cancer cell MCF7 and MDA-MB-231. ST-CY14 inhibits tumor growth and bone metastasis in mouse models .

HY-156018

PI3Kα-IN-13	PI3K	Cancer
PI3Kα-IN-13 (Compound 18a) is a PI3Kα inhibitor (IC₅₀: 2.5 nM). PI3Kα-IN-13 induces tumor cell apoptosis. PI3Kα-IN-13 inhibits cancer cell proliferation with IC₅₀s of 0.75 μM (MCF-7), 3.79 μM (HCT-116), 13.71 μM (MDA-MB-231), 9.85 μM (SW620), respectively. PI3Kα-IN-13 inhibits tumor cell colony formation, migration and invasion .

HY-169382

Melatonin-Tamoxifen Conjugate	Melatonin Receptor	Cancer
Melatonin-Tamoxifen Conjugate (compound 16c) is an anticancer drug conjugate composed of Melatonin (HY-B0075) and Tamoxifen (HY-13757A), which is a potent antagonist of ERα (IC₅₀=863 nM). Melatonin-Tamoxifen Conjugate binds to MLT receptor (K_i=3.1 nM) and promotes β-arrestin (EC₅₀=914 nM) and ERK activation (EC₅₀=98 nM) in cells expressing hMT1 receptor. Melatonin-Tamoxifen Conjugate against several common cell lines MCF-7, MDA-MB-231, and HT-1080 with IC₅₀s of 6.8 μM, 6.4 μM, and 1.7 μM, respectively.

HY-155180

FD2056	PI3K	Cancer
FD2056 is a potent and orally active PI3K inhibitor. FD2056 inhibits PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ with IC₅₀s of 0.30, 0.80, 1.10, 0.42 nM. FD2056 also inhibits CDK2-CyclinA2 and CDK4-CyclinD3 with IC₅₀ of 115.95 and 2782.15 nM. FD2056 inhibits breast cancer cell proliferation with IC₅₀s of 1.06, 0.04, 1.40 μM for MDA-MB-231, MDA-MB-468, MCF-7 cells. FD2056 also induces cancer apoptosis and inhibits tumor growth .

HY-123715

Anticancer agent 255	Apoptosis	Cancer
Anticancer agent 255 is a monocarbonylated curcumin-1,2,3-oxazole conjugate with significant anticancer activity. The IC₅₀ values of Anticancer agent 255 in prostate cancer cells PC-3 and DU-145 are 8.8μM and 9.5μM respectively. The IC₅₀ values of Anticancer agent 255 against breast cancer cells MCF-7, MDA-MB-231 and 4T1 are 6μM, 10μM and 6.4μM, showing good anti-cancer activity Effect. Anticancer agent 255 can induce mitochondria-mediated apoptosis in cancer cells and prevent cell cycle progression. Anticancer agent 255 down-regulated the cell proliferation marker PCNA and inhibited the activation of cell survival proteins. Anticancer agent 255 up-regulated the pro-apoptotic protein Bax and down-regulated the anti-apoptotic protein Bcl-2 .

HY-162805

iNOS/TopoI-IN-1	NO Synthase Topoisomerase Apoptosis NF-κB	Inflammation/Immunology Cancer
iNOS/TopoI-IN-1 (compound AuL9) is a multi-target hybrid molecule with anti-tumor, anti-inflammatory and antioxidant activities. iNOS/TopoI-IN-1 inhibits the growth of breast cancer cells MCF-7 and MDA MB-231 in vitro with IC₅₀ of 3.5 μM and 6.3 μM, respectively, and induces DNA damage and apoptosis of breast cancer cells by inhibiting human topoisomerase I (TopoI) (K_i=2.72 μM). In addition, NOS/TopoI-IN-1 inhibits the expression of iNOS by inhibiting the activation of NF-kB (K_i=1.49 μM) .

HY-161995

FGFR1/VEGFR2-IN-2	Apoptosis Necroptosis FGFR VEGFR PDGFR	Cancer
FGFR1/VEGFR2-IN-2 (compound 6l) is a VEGFR2/FGFR1 dual inhibitor. The IC₅₀ values for VEGFR2 and FGFR1 are 0.025 µM and 0.026 µM respectively, and for EGFR and PDGFR-β, the IC₅₀ values are 0.106 µM and 0.077 µM. FGFR1/VEGFR2-IN-2 showes significant anti-cancer activity (GI=60.38%) on NCI-60 cell line, with an IC₅₀ of 8.51 µM in T-47D cell line and anti-migration. FGFR1/VEGFR2-IN-2 acts to arrest cells in the G1 phase and promote apoptosis and necrosis; the IC₅₀ for MCF-7 cell line exceeds 100 µM, and the IC₅₀ for MDA-MB-231 is 69.17 µM, non-toxic to normal cells .

HY-134008

Protoapigenone	Apoptosis Bcl-2 Family Caspase	Cancer
Protoapigenone is an antineoplastic agent isolated from ferns. Protoapigenone has significant inhibitory activity against Hep G2, Hep 3B, MCF-7, A549 and MDAMB-231, with IC₅₀s values of 1.60, 0.23, 0.78, 3.88 and 0.27 μg/mL respectively .

Cat. No.	Product Name	Type

HY-126437

Poly-L-lysine hydrobromide (MW 30000-70000)

1 Publications Verification

Drug Delivery

Poly-L-lysine hydrobromide (MW 30000-70000) is a water-soluble synthetic polypeptide. Poly-L-lysine hydrobromide (MW 30000-70000) downregulates Bcl-2 and upregulates Bax and p53 proteins. Poly-L-lysine hydrobromide (MW 30000-70000) promotes Apoptosis and reduces VEGF expression. Poly-L-lysine hydrobromide (MW 30000-70000) shows anticancer activity against a variety of tumors. Poly-L-lysine hydrobromide (MW 30000-70000) can also be used as a coating material .

Cat. No.	Product Name	Target	Research Area